|
1. BIOLOGIE
|
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Larotrectinib for treating NTRK fusion-positive solid tumours [NICE]
|
|
|
|
|
|
More evidence on larotrectinib is being collected until there are enough data to address the committee’s uncertainties. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.
|
|
|
|
|
|
|
5.5.10 ASCO (HÉMATO)
|
|
|
|
|
5.5.2 ASCO (SEIN)
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.15 LUTTE CONTRE LES CANCERS - COVID-19
|
|
|
The unexpected side effect of Covid-19 [CNN]
|
|
|
|
|
|
Suspending cancer screening is another important area to study. There is little doubt, for example, that the decline in mammography will lead to fewer breast cancers diagnosed. But is that a bad thing or good thing? One opportunity is to study what happens to US cancer statistics when screening is resumed.
|
|
|
|
|
|
|